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Abstract
Elevated blood pressure (BP) is a major global risk factor for cardiovascular disease. Genome-wide association studies have
identified several genetic variants at the NPR3 locus associated with BP, but the functional impact of these variants remains to
be determined. Here we confirmed, by a genome-wide association study within UK Biobank, the existence of two independent
BP-related signals within NPR3 locus. Using human primary vascular smooth muscle cells (VSMCs) and endothelial cells (ECs)
from different individuals, we found that the BP-elevating alleles within one linkage disequilibrium block identified by the senti-
nel variant rs1173771 was associated with lower endogenous NPR3 mRNA and protein levels in VSMCs, together with reduced
levels in open chromatin and nuclear protein binding. The BP-elevating alleles also increased VSMC proliferation, angiotensin
II-induced calcium flux and cell contraction. However, an analogous genotype-dependent association was not observed in vas-
cular ECs. Our study identifies novel, putative mechanisms for BP-associated variants at the NPR3 locus to elevate BP, further
strengthening the case for targeting NPR-C as a therapeutic approach for hypertension and cardiovascular disease prevention.
†These authors share the senior authorship.
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Introduction
As a complex quantitative trait, high blood pressure (BP) is the
leading risk factor for cardiovascular disease which is influ-
enced by genetic variation and lifestyle factors. Genome-Wide
Association Studies (GWAS) in BP have shown that inter-
individual variation in systolic and diastolic BP (SBP and DBP),
pulse pressure (PP) and mean arterial pressure is associated
with single nucleotide polymorphisms (SNPs) at the natriuretic
peptide receptor C (NPR3) locus in different ancestries (1–4). The
validated variants in the NPR3 30 flanking region that link to SBP
and DBP are rs1173771 in Europeans (2) and rs1173766 in East
Asians and Japanese (5). Furthermore, one-third SNP in this re-
gion, rs1421811, has been associated with SBP in a population of
European ancestry (6). However, the molecular and cellular ba-
sis for these genetic associations remains to be elucidated.
NPR3 encodes natriuretic peptide receptor C (NPR-C). This
protein has a high affinity with all three types of natriuretic
peptides (NPs). NPR-C is widely thought to function as a sys-
temic clearance receptor that removes NPs from the circulation
by facilitating NP internalization and degradation (7–9).
Upregulation of NPRC in adipose and muscle tissues in obese
hypertensive patients (10,11) and reduced BP in global Npr3
knockout mice (12) support a role of NPR-C as a clearance recep-
tor in BP control. Recently, accumulated evidence has suggested
NPR-C also plays a role in cell signalling coupling to Gi (13–15)
and mediates some of the cardioprotective actions of NPs and
their involvement in the pathogenesis of hypertension (16,17).
Perhaps the best example is the identification of C-type natri-
uretic peptide (CNP)/NPR-C signalling as a functional pathway
in the regulation of vascular tone (18). This is likely to result
from CNP binding to NPR-C, stimulating Gi and activating potas-
sium ion (Kþ) conductance, leading to hyperpolarization and
relaxation of vascular smooth muscle cells (VSMCs) (19).
Furthermore, we have demonstrated that administration of
synthetic NPR-C agonists exerts a dose-dependent and clinically
valuable hypotensive impact in vivo (20). This is complemented
by observations that cANF4–23, a ring-deleted analogue of ANP
that specifically interacts with NPR-C (7), reduces BP in sponta-
neously hypertensive rats (21).
There are very few studies that have functionally character-
ized the effects of the BP-associated variants in humans. In this
study of the NPR3 locus, we investigate whether validated SNPs
influencing BP have an impact on human VSMC and endothelial
cell (EC) NPR-C expression, proliferation, migration, intracellular
calcium flux and cell contraction in vitro.
Results
Two independent BP-associated genetic signals at the
NPR3 gene locus detected using a GWAS within UK
Biobank
Recent publication has suggested that two independent BP-
associated genetic signals exist at the NPR3 locus (3). To deter-
mine if there were additional independent signals at this locus,
we utilized the large UK Biobank (UKB) cohort (https://www.
ukbiobank.ac.uk/; date last accessed October 11, 2017) with data
of 140 886 individuals of European ancestry. It was observed
that there were two independent, significant signals with lead
SNPs rs1173727/rs7733331 [(linkage disequilibrium (LD) block 1
with published SNP rs1173771)] and rs1421811 (LD block 2) re-
spectively at NPR3 locus (Fig. 1A–C). The effect size and P-values
of these BP-associated variants are shown in Table 1 (for SBP)
and Supplementary Material, Table S1 (for DBP and PP).
Conditional analysis (Fig. 1D) provided further validation for our
approach herein that there were no additional independent sig-
nals, confirming a total of two independent signals at this locus.
For example, the association of SNP rs7733331 with SBP was no
longer significant (P¼ 0.37) after conditioning on the two pub-
lished SNPs. Nevertheless, there was still some evidence
(Pcond< 1.0 104) of residual association remaining for SNPs
rs1173743 and rs1173756 (Table 1), reflecting a weak residual as-
sociation existing in the rs1173771 LD block.
BP-elevating allele in rs1173771 LD block decreases
NPR3 expression
To explore the effect of BP-associated SNPs on NPR3 expression,
quantitative reverse transcriptase polymerase chain reaction
(qRT-PCR) was performed on primary arterial VSMCs derived
from umbilical cords from different neonates (n¼ 100), an inde-
pendent resource unrelated to the UKB cohort. Reduced NPR3
mRNA levels were observed in VSMCs homozygous for the BP-
elevating allele (EE) in the rs1173771 LD block, when compared
with BP-lowering allele homozygous (LL) VSMCs (Fig. 2A).
Consistent with the qRT-PCR results, allelic expression imbal-
ance analysis for the 3’-UTR SNP rs1173756 (r2 ¼ 0.78 in CEU and
r2¼1.00 in CHB/JPT with rs1173771) showed the BP-elevating al-
lele (E) had lower expression levels when compared with the
BP-lowering allele (L) in mRNA (Fig. 2B). Western blotting also
revealed that NPR-C protein levels were lower in VSMCs of the
EE genotype compared with the LL genotype (Fig. 2C). In concert,
these observations strongly support a functional influence on
NPR-C expression at a transcriptional level of the specific NPR3
SNPs tested or other functional variants within the LD block.
rs1173771 and rs1173747 reside in open chromatin
regions and affect nuclear protein binding
The SNPs in the rs1173771 LD block are located in non-coding
regions. Bioinformatic analysis indicated some of these SNPs re-
side in regions with transcription regulatory features such as
histone modification marks (e.g. H3K27ac) and transcriptional
factor binding (Supplementary Material, Table S2). Therefore,
we investigated if these SNPs had any effect on these features.
Formaldehyde-assisted isolation of regulatory elements (FAIRE)
followed by allelic imbalance assays in VSMCs revealed that the
relative abundance of L allele versus E allele of rs1173771 (inter-
genic SNP in the downstream of NPR3 gene) was significantly
higher in FAIRE DNA compared with the reference DNA (Fig.
3A). Electrophoretic mobility shift assay (EMSA) with VSMC nu-
clear extracts demonstrated differential nuclear protein binding
to the different alleles of rs1173771 (Fig. 3B). This supports the
FAIRE findings that the L allele of rs1173771 is more likely to be
in an open chromatin configuration and therefore be more ame-
nable to transcription. ChIP with an anti-H3K27ac antibody fol-
lowed by allelic imbalance assays of rs1173771 showed similar
results (Fig. 3C). A luciferase reporter gene assay also demon-
strated the L allele increased the transcriptional activity
(Fig. 3D).
One intronic SNP, rs1173747, also presented an allelic differ-
ence as rs1173771 in enrichment in open chromatin (Fig. 4A), in-
teraction with VSMCs nuclear extracts in vitro (Fig. 4B), and
transcriptional activity (Fig. 4C), although no association be-
tween the rs1173747 flanking region with H3K27ac. These re-
sults suggest that rs1173771 and rs1173747 can modulate NPR3
transcription by allele-dependent effects on chromatin and
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transcription factor binding. UKB GWAS conditional analysis as
above indicated a weak residual association (Pcond< 1.0 10–4)
remaining for SNPs rs1173743 and rs1173756 (both in strong LD
with intronic SNP rs1173747; r2 > 0.95) existing in the rs1173771
LD block. This provides support for our findings that rs1173771
and rs1173747 may both be acting as functional SNPs in the sin-
gle LD block.
Association of BP-elevating allele with increased VSMC
proliferation
To assess the potential effect of BP-associated variants on
VSMC proliferation, we conducted cell counting assays using
Cell Counting Kit-8 (CCK-8). We found that VSMCs carrying the
E allele had an innately increased proliferation rate when com-
pared with cells with LL (Fig. 5A), linking to allelic difference
Figure 1. Regional plots for association of NPR3 variants with SBP/DBP/PP within the UK Biobank cohort. (A–C) Genome-wide primary association analysis of main ef-
fects for medication-adjusted SBP, DBP and PP traits using the UK Biobank cohort (N¼140 886) showed two signals at the NPR3 locus. The sentinel SNPs in these two in-
dependent linkage disequilibrium (LD) blocks are labelled in red or light blue text, respectively. The purple dot indicates rs1173771, the lead SNP in our previous GWAS
study (2), and r2 measures of LD are shown in relation with rs1173771. (D) A conditional analysis based on the two published lead SNPs, rs1173771 and rs1421811, indi-
cated the presence of a weak residual signal with rs1173747 in the rs1173771 LD block. Note that the variants (dark blue dots) upstream of rs1173747 were not signifi-
cantly associated with BP in the primary main association analysis, so are not of interest within the conditional analysis.
Table 1. Association between NPR3 variants and blood pressure traits in UK Biobank cohort
Candidate SNPs Positions on Chr 5 (bp) EA AA EAF Phenotypes SBP effect (mmHg) P-value (SBP) Conditional P-value (SBP)
Block 1 rs1173727 32 830 521 C T 0.60 SBP, DBP, PP 0.75 (0.07) 3.111026 0.26
rs7733331 32 828 846 C T 0.60 SBP, DBP, PP 0.75 (0.07) 4.441026 0.37
rs1173771 32 815 028 C T 0.60 SBP, DBP, PP 0.74 (0.07) 3.261025 –
rs1173766 32 804 528 C T 0.60 SBP, DBP, PP 0.74 (0.07) 7.271015 2.82104
rs1173747 32 782 152 A C 0.53 SBP, DBP, PP 0.51 (0.07) 1.971013 6.52104
rs1173756 32 789 852 C T 0.53 SBP, DBP, PP 0.50 (0.07) 1.191012 9.57105
rs1173743 32 775 047 T G 0.52 SBP, PP 0.48 (0.07) 1.131011 6.31105
Block 2 rs1421811 32 714 270 C G 0.39 SBP, DBP, PP 0.68 (0.07) 2.151021 
rs3828591 32 713 108 G C 0.39 SBP, DBP, PP 0.68 (0.07) 3.551021 NA
rs3762988 32 709 653 C T 0.39 SBP, DBP, PP 0.66 (0.07) 2.791020 NA
rs7729447 32 689 773 G A 0.32 SBP, PP 0.58 (0.07) 1.361014 NA
Genetic position is based on Build 37 of a reference genome. P<5108 was used a threshold to determine the association with BP traits. The effect is presented as
unit change (mmHg) with standard error (SE) in systolic blood pressure (SBP) per copy of effect allele.
Chr, chromosome; EA, effect allele; AA, alternative allele; EAF, effect allele frequency; DBP, diastolic blood pressure; PP, pulse pressure.
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of NPR3 levels. Exogenous CNP (100 nmol/l) or NPR-C specific
agonist cANF4–23 (100 nmol/l) caused an equivalent genotype-
dependent effect on proliferation (Fig. 5B), with a signifi-
cantly greater inhibition on cells carrying LL in the presence of
cANF4–23 (Fig. 5C).
No association between NPR3 risk variants and VSMC
migration
To investigate whether BP-associated NPR3 variants influence
VSMC migration, we performed in vitro scratch assays on
primary VSMCs. However, no association was detected
Figure 2. Blood pressure associated variants affect NPR3 expression in human VSMCs. For all panels, ‘E’ stands for the BP-elevating allele for each SNP, ‘L’ denotes the
BP-lowering allele for each SNP. (A) Relative mRNA levels of NPR3 in VSMCs was determined by quantitative reverse-transcription polymerase chain reaction and stan-
dardized against the reference gene 18S. Mean6SEM, **P <0.01. (B) The relative peak heights of two alleles of the 30 UTR SNP rs1173756 (r2¼0.78 with lead SNP
rs1173771) in sequencing chromatograms from genomic DNA and complementary DNA (cDNA) of VSMCs. Mean6SEM, **P <0.01. (C) A representative image of western
blot analysis of NPR-C protein in VSMCs with b-actin as a loading control, Mean6SEM, *P <0.05.
Figure 3. The BP-associated variant rs1173771 affects chromatin status and nuclear protein binding. In this figure, ‘E’ indicates BP-elevating allele, ‘L’ denotes BP-lower-
ing allele. (A) Formaldehyde-assisted isolation of regulatory elements followed by allelic imbalance assay by Sanger sequencing. Left panel: Representative images
showing different peak heights of the E and L alleles of rs1173771 in chromatograms derived from reference (Ref.) DNA and FAIRE DNA, respectively. Right panel: values
in the bar chart are mean6SEM of n¼6 heterozygous samples, *P <0.05. (B) Representative result of an electrophoretic mobility shift assay with the use of biotin-la-
belled double-stranded oligonucleotide probes and unlabelled competitors of the E and L alleles of rs11737711, and nuclear protein extracts from VSMCs. (C) Chromatin
immunoprecipitation with an anti-H3K27ac antibody and IgG (the negative control) in heterozygous VSMCs. Upper left panel: PCR amplified DNA containing the
rs1173771 site derived from anti-H3K27ac precipitated DNA, anti-H3K4me1 precipitated DNA and input DNA, respectively. Lower left panel: representative chromato-
graphs showing the peak heights of the E and L alleles of rs1173771 from Input and precipitated DNA, respectively. Right panel: values in the bar chart are mean6SEM
of seven heterozygous samples, **P <0.01. (D) Relative activity of the rs1173771 E and L alleles, respectively, in driving firefly luciferase reporter gene expression in
transfected VSMCs, standardized for transfection efficiency. Mean6SEM, **P <0.01, ***P <0.001.
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between NPR3 variants and cell migration (Supplementary
Material, Fig. S2).
BP-elevating allele increases intracellular calcium
response and cell contraction to angiotensin II in VSMCs
To evaluate the role of BP-associated variants in stimulated
changes in intracellular calcium flux in VSMCs, a Fluorescent
Imaging Plate Reader (FLIPR)-based calcium assay was con-
ducted. Cells among genotypes were stimulated with angio-
tensin (Ang) II (10 or 100 nmol/l, representing approximate
EC50 or EC90 values, respectively, see Supplementary Material,
Fig. S2). We found that VSMC homozygous samples with EE ex-
hibited an augmented intracellular calcium level along with a
shorter time to peak response following stimulation with Ang
II (at 10 and 100 nmol/l) in contrast to LL (Fig. 6A), indicating a
Figure 4. The BP-associated variant rs1173747 affects chromatin status and nuclear protein binding. In this figure, ‘E’ indicates BP-elevating allele, ‘L’ denotes BP-lower-
ing allele. (A) Formaldehyde-assisted isolation of regulatory elements followed by allelic imbalance assays by Sanger sequencing. Representative images showing dif-
ferent peak heights of the E and L alleles of rs1173747 in chromatograms derived from reference (Ref.) DNA and FAIRE DNA. Mean6SEM of n¼6 heterozygous samples,
*P <0.05. (B) Representative result of electrophoretic mobility shift assay with the use of biotin-labelled double-stranded oligonucleotide probes and unlabelled compet-
itors of the E and L alleles of rs1173747 and nuclear protein extracts from VSMCs. (C) Relative activity of the rs1173747 E and L alleles, respectively, in driving firefly lu-
ciferase reporter gene expression in transfected VSMCs, standardized for transfection efficiency. Mean6SEM, **P <0.01, ***P <0.001.
Figure 5. The BP-elevating variant at NPR3 locus is associated with increased human VSMCs proliferation. VSMCs in the absence and presence of C-type natriuretic
peptide (CNP; 100 nmol/l) and the NPR-C specific agonist (cANF4–23; 100 nmol/l) for 24 h were analysed for proliferation rate. Cell proliferation over the 24-h period was
calculated as (OD450 at 24 hOD450 at baseline)/OD450 at baseline. ‘E’ indicates the BP-elevating allele, ‘L’ denotes the BP-lowering allele. (A) Differences in prolifera-
tion between untreated cells of different genotypes. Representative images of DAPI stained cells of the three different genotypes at baseline and 24 h. Scale
bars¼200mm. Mean6SEM, *P <0.05. (B) Differences in proliferation between CNP or cANF4–23 treated cells of different genotypes, and (C) Inhibitory effects of CNP and
cANF4–23 on proliferation of cells of different genotypes, calculated by (OD450 at 24 h of untreated cellsOD450 at 24 h of CNP-treated or cANF4–23-treated cells)/OD450
at 24 h of untreated cells. Mean6SEM, *P <0.05.
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genotype effect on intracellular calcium response to Ang II.
We next examined the effect of CNP and cANF4–23, on calcium
flux. In the presence of CNP (1 lmol/l) or cANF4–23 (1 lmol/l),
VSMCs continued to exhibit the same genetic difference in
Ang II-stimulated samples (Fig. 6B), with a trend towards a
slightly lower effect of the BP-elevating allele samples (Fig.
6C), in accordance with our findings of allelic association of
NPR-C expression level.
To investigate the potential influence of BP-associated vari-
ants in VSMC contraction, assessment of single cell contraction
in response to 100 nmol/l Ang II was performed. In this setting
VSMCs with EE had stronger contraction in response to Ang II
Figure 6. The BP-elevating allele at NPR3 locus increases Ang II-induced intracellular calcium changes in human VSMCs. Human VSMCs were incubated with or with-
out C-type natriuretic peptide (CNP; 1 lmol/l) and the NPR-C specific agonist cANF4–23(1 lmol/l), and then exposed to Ang II (10 or 100 nmol/l). ‘E’ indicates the BP-ele-
vating allele, ‘L’ denotes the BP-lowering allele. (A) Representative images of intracellular calcium changes among genotypes under stimulation of 100 nmol/l Ang II. (B)
Differences between genotypes in intracellular calcium changes in response to Ang II in the absence of CNP or cANF4–23. Differences between genotypes in intracellular
calcium level changes in response to Ang II (C) and drug inhibitory effect (D) in the presence of CNP or cANF4–23. Mean6SEM, *P <0.05, **P <0.01.
Figure 7. The BP-elevating allele at NPR3 locus enhances Ang II-induced human VSMCs contraction. ‘E’ indicates the BP-elevating allele, ‘L’ denotes the BP-lowering al-
lele. (A) Representative images of VSMCs of the three different genotypes at baseline (before stimulation) and 30 min after treatment with 100 nmol/l Ang II, respec-
tively. White dash lines show the original size of cells at baseline, and the black ones outline the sizes at 30 min in the merged panel. Scale bars¼50mm. (B) Differences
in 100 nmol/l Ang II stimulated VSMC contraction of different genotypes at 15, 30, 45, 60 min. Mean6SEM, *P<0.05.
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after 15, 30 and 45 min (Fig. 7), mirroring the findings linking ge-
notype to NPR-C expression.
Association between the other (rs1421811) LD block at
NPR3 gene locus and VSMCs phenotypes
We also evaluated the other independent LD block based on the
SNP rs1421811. A non-significant trend was observed that the
rs1421811 BP-elevating allele homozygous VSMCs (EE) had a mar-
ginally lower NPR3 mRNA and protein level, without significant dif-
ference in cell proliferation or migration (Supplementary Material,
Fig. S3). However, a higher calcium change in response to
100 nmol/l Ang II was detected in its EE (Supplementary Material,
Fig. S3), consistent with the findings in rs1173711 LD block.
Effect of the BP-associated variants on vascular ECs
NPR3 gene expression, and cell activities
In addition to the assays in VSMCs described above, we investi-
gated whether the BP-associated variants in rs1173771 or
rs1421811 LD block affect NPR3 expression and cell activities in
primary venous ECs derived from umbilical cords from different
neonates (n¼ 106). Quantitative RT-PCR analysis showed that
the E allele has slightly lower NPR3 mRNA levels in ECs but
without statistical significance, despite allelic expression imbal-
ance analysis also suggested a decreased mRNA level of the E
allele in rs1173771 LD block (Supplementary Material, Fig. S4).
Cell viability and migration ability were also investigated and
showed no significant genetic association between the NPR3 BP-
related variants in rs1173771 LD locus and these phenotypes.
Whereas, the L allele in rs1421811 LD block drove a near-
significant increase of NPR3 expression and elevated cell prolif-
eration, but not migration (Supplementary Material, Fig. S5).
Discussion
Previous genetic studies identified multiple SNPs associated
with BP and hypertension susceptibility. The challenge now is
to unravel the causative mechanisms and biology behind these
associated gene loci. Two independent signals at the NPR3 locus
have been associated with a modest effect on BP in several stud-
ies (2,3,6). We validated both signals (with sentinel SNPs
rs1173771 and rs1421811, respectively) for BP in 140 886 UKB
participants and confirmed by regional conditional analysis for
BP traits (SBP, DBP and PP) that the variants we have studied in
these two LD blocks explain the observed association, with no
additional independent signals existing.
Herein, we establish an ex-vivo genotype-specific human labo-
ratory experimental strategy that reveals the biological impact of
SNPs at the NPR3 locus in VSMCs and ECs. We discovered that the
BP-elevating alleles of the associated variants in rs1173771 LD
block exhibit lower NPR3 expression in VSMCs. Our findings also
show that these non-coding variants (intergenic SNP rs1173771
and intronic SNP rs1173747) have an allele-dependent effects on
open chromatin and transcription factor binding, thereby active
transcription of NPR3 occurring at lower levels with BP-elevating
alleles, although it is also conceivable that the lower NPR3 expres-
sion levels may be also attributable to a compensatory mecha-
nism which attempts to diminish the NP clearance. Furthermore,
our regional conditional analysis within the UKB indicates that
there is a weak residual association between rs1173771 and
rs1173747, implying rs1173771, rs1173747 or variants within the
haplotype block might be acting as functional variants, however,
the causal variant(s) and the precise mechanism behind still
needs to be further identified.
In keeping with molecular, physiological and pharmacologi-
cal evidence that NPR-C exerts an impact on vascular smooth
muscle tone (20,22,23), we demonstrate that the BP-elevating al-
lele homozygous cells exhibit augmented proliferation, Ang II-
stimulated intracellular calcium response and cell contraction
in human VSMCs. Although several models for the pathogene-
sis of hypertension have been proposed, there are at least two
plausible mechanisms where increased VSMC proliferation and
contractility can lead to raised BP: (i) increasing the vascular
tone of the resistance arteries, consequently influencing sys-
temic vascular resistance; and (ii) altering renal vascular tone
and perfusion, secondarily affecting pressure-natriuresis
(24,25). Taken together, these findings provide a mechanism
whereby NPR3 variants at the rs1173771 LD block could impact
on BP homeostasis, through decreasing the receptor expression
and subsequent modification of human VSMC reactivity
(Supplementary Material, Fig. S6). In addition, functional char-
acterization of the other independent signal with sentinel SNP
rs1421811 was also undertook. An allelic-specific impact on
VSMCs calcium response to a higher dose of Ang II was de-
tected, a pattern in accord with rs1173771, supporting its genetic
association with BP.
To date, the biological roles of NPR-C are not completely un-
derstood. This receptor has long been implicated in the binding,
internalization and degradation of NPs (7). BP in global Npr3
knockout mice was found to be 8 mmHg lower than wild-type
mice (13), which is consistent with the notion that NPR-C exerts a
cardiovascular effect by mediating clearance of NPs. However,
there was no change of plasma levels of NPs in the NPR-C knock-
out mice, which suggests that NPR-C may have other roles in ad-
dition to NP clearance. More recently, there is accumulating
evidence suggesting that NPR-C has a function in intracellular
signalling. For instance, it has been shown that administration of
synthetic NPR-C agonists exerts a dose-dependent hypotensive
impact in mice (20) and reduces the elevated BP in spontaneously
hypertensive rats through inhibiting Gia proteins and nitroxida-
tive stress in vivo (21). Therefore, it is possible that NPR-C has
both NP clearance and signalling functions.
With regard to its signalling function, previous studies have
indicated that NPR-C supresses VSMC proliferation in response
to CNP or cANF4–23 (22,23,26). NPR-C also could reduce the L-type
calcium current (ICa-L) via binding with CNP in mouse sinoatrial
node myocytes (27), and Ang II-stimulated mesenteric artery
SMC calcium flux (20). In this study, we observed such a similar
inhibitory effect of CNP and cANF4–23 on human VSMC prolifera-
tion and calcium responses to Ang II in a genotype-dependent
manner, which correlates with NPR3 gene expression levels,
supporting the hypothesis that increased expression of NPR3 in
individuals enhances a protective signalling pathway. Notably,
genetic differences in VSMCs proliferation, calcium flux and
contraction were observed in the absence of exogenous agonist.
This might be explained by the inherent production of CNP by
human VSMCs in a cell culture environment (Supplementary
Material, Fig. S1), although the vast majority of in vivo vascular
CNP originates from the ECs. Another plausible explanation
might be the intrinsic activity of NPR-C, which is a common
facet of GPCR biology (28,29), thereby potentially generating a
signal even in the absence of an agonist.
Although our study detected an effect of BP-associated SNPs
on VSMCs NPR3 expression and cell activities, we did not dis-
cern a statistically significant influence in our experiments of
ECs. However, a trend was observed in some of ECs assays. For
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example, ECs with the BP-lowering allele tended to have greater
NPR3 mRNA expression, and exhibited accelerated proliferation
(particularly those with SNPs in the rs1421811 LD block). This is
consistent with our previous work which demonstrated that
NPRC stimulation by cANF4–23 increases EC proliferation (23).
Therefore, it is possible that the effect sizes were smaller in ECs
and thus a large sample size would be required for the differ-
ences to reach statistical significance.
It is evident that SNPs in the protein-coding region may
merely comprise 7% of complex disease-associated variants,
while the majority of associated SNPs are either intronic or
intergenic (30,31). To date, only a small fraction of the func-
tional impact of complex trait variants on the development of
disease have been unravelled. Our functional experiments for
the intergenic SNP rs1173771 and intronic SNP rs1173747 pro-
vide one of the early examples of the mechanistic impact of as-
sociated complex trait variants at a BP level. Moreover, we show
the possibility of more than one SNP acting as a functional vari-
ant in a single LD block indicating the complexity of biological
impact even within one signal associated with BP.
Our study has some limitations. Although we have demon-
strated that the BP-associated SNPs at the NPR3 locus affect NPR3
expression and VSMC function, several questions are still
unclear. First, we have not determined the intracellular signalling
pathways that mediate the effect of NPR3 SNPs. Second, NPR-C is
thought to be able to act as a clearance receptor and therefore it
is possible that the functional NPR3 variants could have an effect
on NP clearance and consequently an influence on plasma levels
of NPs. We have not investigated whether this is the case, but a
previous study reported an association between a NPR3 gene pro-
moter SNP and plasma ANP levels in obese hypertensives (32). On
the other hand, studies of NPRC-KO mice did not show changes
in plasma levels of NPs but found ANP having a prolonged half-
life (12). Third, it is unknown whether the decreased NPR-C ex-
pression associated with NPR3 SNPs could in turn lead to a com-
pensational change in the expression of NPR-B and whether the
effect of NPR3 SNPs on VSMC proliferation/calcium/contraction to
Ang II could be abolished by an NPR-B antagonist. Fourth, al-
though our study has focused on VSMCs and ECs, it is possible
that the BP-associated NPR3 SNPs may affect NPR3 expression
and NPR-C function also in other systems, such as in the auto-
nomic or central nervous system and in skeletal growth, which
may also impact on BP. These questions warrant investigations
in future research.
Over 220 genetic loci have been validated that harbour variants
influencing BP level and risk of hypertension (3,33–35). These
newly discovered candidate genes, proteins and their related path-
ways can represent potential new drug targets. Here, we used a
human laboratory experimental strategy to elucidate the func-
tional impact of genetic variants associated with BP at the NPR3 lo-
cus. Our findings in VSMCs provide compelling evidence for an
important role of NPR-C in BP regulation and the development of
hypertension. Furthermore, these data provide further confirma-
tion that NPR-C should be considered as a potential therapeutic
target for hypertension, and we have previously reported the effi-
cacy of a lead compound in experimental models (20).
Materials and Methods
Genome-wide association analysis and genotype model
analysis of BP traits in UKB
The full genetic data for the first 150K UKB participants was
imputed by a merged UK 10K sequencingþ 1000 genomes
reference panel (36). A subset of maximum of N¼ 140 886 of
unrelated Caucasian individuals with good quality data was fi-
nally analysed. Baseline characteristics and the quality control
procedures see previous publication (37). We focused on data
extracted from the known NPR3 region (Chr 5: 32 214 276–
33 314 487), and our SNPs of interest within the region were well
imputed with very high imputation quality (INFO> 0.97). The
phenotypic variable for PP was derived as SBP–DBP, per the
medication-adjusted traits. A proportion (21.4%) of the UKB par-
ticipants are reported to be taking anti-hypertensive medica-
tions. For these individuals, þ15 mmHg was added to their SBP
measurement, and þ10 mmHg to DBP, by the standard adjust-
ment convention used in all BP GWAS analyses. Exclusions
such as renal and heart failure are not considered within the
standard analyses.
For GWAS, linear regression analyses of the three (untrans-
formed) continuous, medication-adjusted BP traits (SBP, DBP,
PP) were performed using SNPTEST software under an additive
genetic model. Each analysis included the following covariates:
sex, age, age2, BMI, top 10 PCs and UKB cohort status, where the
UKB cohort status was a binary indicator. The conditional anal-
yses within the NPR3 region conditioning on the published SNPs
were also performed using SNPTEST software, using the same
phenotypic, covariates data and analysis model as for the
GWAS.
Cell samples
This study had ethical approval from Queen Mary, University of
London (ref: 08/H0704/140). All human tissue samples were fully
anonymized before distribution to the recipient analysis groups,
as per ethical approval. Primary human arterial VSMCs and ve-
nous ECs were isolated from umbilical cords from different neo-
nates, an independent resource unrelated to the UKB cohort,
using arterial media explant culture technique and collagenase
digestion method, respectively, as previously described (38,39).
VSMCs were cultured in Dulbecco’s Modified Eagle Medium
(DMEM) supplemented with 15% fetal bovine serum, while ECs
were cultured in Medium 199 with supplements. The VSMCs
and ECs were used in all experiments in this study, except the
luciferase reporter gene assays in which a rat thoracic aorta
VSMC line (A10) (ATCC, CRL-1476) was employed. Cells used in
these experiments were at passage 2–6, and there were no dif-
ferences between the different genotypes for each of the SNPs
studied, in passage number or the level of confluency in each
assay.
DNA extraction and genotyping
Genomic DNA from VSMCs and ECs was extracted using the
DNeasy Blood & Tissue Kit (Promega) and genotyped by the
KBiosciences Competitive Allelic-specific PCR SNP genotyping
system (40). The primers used are listed in Supplementary
Material, Table S3.
Quantitative reverse-transcription polymerase chain
reaction
The total RNA was extracted from VSMCs and ECs, using the SV
Total RNA Isolation System (Promega), then reverse transcribed
into complementary DNA (cDNA) (Promega, M170). qRT-PCR for
NPR3 and 18S (internal reference) was performed on cDNA in
duplicate by using Power SYBRVR Green PCR Master Mix kit (Life
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Technologies) using real-time quantitative PCR instrument (ABI
7900HT machine). Primer sequences used are listed in
Supplementary Material, Table S3. The expression level of NPR3
relative to 18S from three independent experiments was then
determined by the 2-DDCt method (41).
Allelic expression imbalance assay
End-point PCR for the amplification of the rs1173756 (30-UTR
SNP, highly linked with GWAS lead SNP rs1173771) flanking
DNA sequence was performed on genomic DNA and cDNA, re-
spectively, from heterozygous samples using the PCR Master
Mix Kit (NovagenVR ). PCR products were cleaned up and then
subjected to Sanger sequencing commercially at Genome
Centre, Queen Mary University of London. The Peak Picker pro-
gram was utilized to determine the relative peak heights of al-
leles in the sequencing chromatograms from genomic DNA and
cDNA samples, respectively (42). Primers sequences used are
listed in Supplementary Material, Table S3.
Western blot analysis
Cell lysates were quantified (Thermo Scientific, 23225), sub-
jected to sodium-dodecyl-sulphate polyacrylamide gel electro-
phoresis (SDS-PAGE) and transferred to a polyvinylidene
fluoride (PVDF) membrane. Blots were incubated with primary
antibodies to NPR-C (1:1000 dilution, Abcam, Cat No. Ab123957)
or b-actin (1:1000 dilution, Abcam, Cat No. ab 8226), respectively,
followed by incubation with HRP-conjugated secondary anti-
body (1:3000 dilution, Cell Signaling, Cat No. #7076 S), and de-
tected by autoradiography.
Formaldehyde-assisted isolation of regulatory elements
FAIRE was conducted according to a previous protocol (43).
Heterozygous samples cells were cross-linked with 1% formal-
dehyde, and resuspended in lysis buffer, then sonicated to
shear DNA to lengths between 200 and 800 bp (40 s sonication).
The DNA lysates was subjected to phenol/chloroform/isoamyl
alcohol (Sigma) to extract the open chromatin. The samples
were de-crosslinked by heating and the residual proteins were
digested by proteinase K (Promega). The DNA samples were
subjected to allelic imbalance analysis as described above.
Primer sequences used are listed in Supplementary Material,
Table S3.
Chromatin immunoprecipitation
VSMCs heterozygous for SNPs rs1173771 and rs1173747 were
crosslinked by 1% formaldehyde. Cells were lysed utilizing lysis
buffer and the chromatin was sheared as described above. One
aliquot of sheared chromatin was taken as ‘Input’ sample.
Other aliquots were diluted with ChIP dilution buffer, and incu-
bated with anti-human H3k27ac antibody (Abcam, Cat No.
ab4729) or normal IgG (Santa Cruz, Cat No. sc-2025) overnight at
4 C. A 10 ng Protein A/G Plus-Agarose (Santa Cruz, Cat No. sc-
2003) was then added to the sample and incubated again for 3 h
at 4 C. The DNA–protein–antibody complexes bound to protein
G-agarose beads were washed with washing buffers. The DNA–
protein complex was eluted from the agarose by adding elution
buffer, de-crosslinked, then input DNA and immunoprecipi-
tated DNA were subjected to allelic imbalance analyses of SNPs
as described above. Primer sequences used are listed in
Supplementary Material, Table S3. Details of buffers utilized in
this assay see Supplementary Material, Table S4.
Electrophoretic mobility shift assay
EMSA was performed as described (44). Double-stranded biotin la-
belled probes (10 femtomoles) were incubated with 8lg VSMCs
nuclear extracts, and/or unlabelled competitors, then subjected
to non-denaturing polyacrylamide gel (6%) electrophoresis.
Oligonucleotide sequences are listed in Supplementary Material,
Table S3. After electrophoresis, blots were transferred to a nylon
membrane (Amersham, RPN119B). The membrane was then
cross-linked at 120 mJ/cm2 for 45–60 s (Biolink, BLX-254E).
Distribution of species containing nucleic acid was finally deter-
mined by a Chemiluminescent Nucleic Acid Detection Module
(ThermoScientific, #89880).
Luciferase reporter gene assay
DNA fragments flanking the BP-associated variants (rs1173771
and rs1173747) (primers see Supplementary Material, Table S3)
were amplified from genomic DNA and inserted upstream of
the SV40 promotor between SacI and MluI in the pGL3-promotor
vector (Promega). A10 cells were cultured in 24-well plates at
5 104/well for 24 h and then transfected with luciferase repor-
ter gene plasmids containing DNA fragments flanking variants,
along with a plasmid containing the Renilla luciferase gene us-
ing transfection reagents (Thermo Scientific, R0532). At 48 h
post-transfection, firefly and Renilla luciferase activities were
measured using the Dual-Luciferase Reporter Assay System
(Promega, E1910). The relative firefly luciferase activity in each
well was calculated with standardization to Renilla luciferase ac-
tivity. All data came from four to six replicate wells.
Cell viability and proliferation assay
VSMCs or ECs were plated into a pre-coated 96-well plate at a
density of 4000 cells/well in triplicate for each group. After over-
night incubation, VSMCs were serum starved for 24 h then
transferred to 15% FBS DMEM with or without 100 nmol/l CNP
(Sigma-Aldrich) or cANF4–23 (Bachem). For ECs, cells were serum
starved in 0.2% BSA M199 for 4 h, then replenished with 15% FBS
M199 with or without 1 nmol/l CNP or cANF4–23. Cells were as-
sayed at baseline under 450 nm in a microplate reader with
CCK-8 reagent, a highly water-soluble tetrazolium salt, WST-8
(Dojindo, Cat No. CK04-11, Japan) and then again after a 24 h in-
cubation with or without treatment. All experiments were con-
ducted in triplicate, and three independent experiments were
carried out for each sample in this assay. Cell proliferation over
the 24-h period was calculated as (OD450 at 24 h OD450 at
baseline)/OD450 at baseline. Inhibitory effects of CNP and
cANF4–23 on proliferation of cells of different genotypes, calcu-
lated by (OD450 at 24 h of untreated cells OD450 at 24 h of CNP-
treated or cANF4–23-treated cells)/OD450 at 24 h of untreated
cells.
Enzyme immunoassay
Growth media in which VSMCs and ECs were cultured for 24 h
with or without serum supplemented was collected from flasks.
Detection of CNP in these cell media was performed using the
commercial enzyme immunoassay (EIA) kit (Pharmaceuticals,
Cat No: EK-012-03) according to the manufacturer‘s instructions.
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The CNP concentrations in samples were calculated by non-lin-
ear regression using Graph Pad Prism version 5 (Graph Pad
Software, CA, USA).
Scratch assay
The assay was carried out according to a previously published
protocol (45). Cells were plated into a 24-well cell plate at a den-
sity of 105 cells/well for VSMCs and 1.5 105 cells/well for ECs to
achieve a confluent monolayer, incubated overnight and serum
starved as described above. A linear wound was then gently in-
troduced in the centre of the cell monolayer using a 200 ll tip.
Cells were then incubated with CNP or cANF4–23 (both final con-
centrations: 100 nmol/l for VSMCs and 1 nmol/l for ECs). Images
were captured at baseline, 6 h using a digital microscope camera
(GXCAM-2TFT).
Calcium flux assay
VSMCs were seeded in black-wall, clear bottomed 96-well
microplates at 7000 cells/well in triplicate overnight before the
assay. The cells were incubated with the loading dye calcium 6
(Molecular Device, R8191) for 2 h at 37 C. The FLIPR was pre-set
to 37 C. Freshly prepared CNP, cANF4–23 [both final concentra-
tions: 1 lmol/l, as in a previous study (20)] or equivolume vehicle
control (double distilled water) was dispensed into wells and in-
cubated for 10 min. Ang II (final concentrations: 10 or 100 nmol/
l) was subsequently dispensed into the wells to induce calcium
flux. Thereafter, the fluorescent signal was detected every sec-
ond for 3 min, with the readings in the first 10 s before stimula-
tors dispensing taken as baseline values (F0). The intracellular
calcium change was calculated using the equation (Fmax – F0)/F0,
where Fmax was the peak value.
VSMC contraction assay
VSMC contraction was assessed by changes in planar surface
under stimulation of Ang II as previously described (46,47). A
200 lL mixture with 5 103 cells were plated in a
35 mm 10 mm petri dish (Corning) and incubated overnight.
The cells were mounted into an onstage incubator with 5% CO2
at 37 C. Ang II with a final concentration of 100 nmol/l was dis-
pensed into the dish and cells incubated for one hour. Images of
the same cells were captured at 1 min before addition of Ang II,
then serially every 15 min for an hour after stimulation, under
phase contrast mode using a digital time-lapse microscope
(Zeiss AxiVert 200 M). The planar surfaces of cells in response to
Ang II were measured before and after stimulator using Image J,
and calculated by the equation: (Spro Spost)/Spro, where Spro was
the cell size at 1 min before stimulation and Spost was the cell
size after treatment at each time point. Each value of individual
sample cell surface size is from six different measurement.
Statistical analyses
Data are presented as arithmetic means6SEM. All datasets
subjected to statistical analysis were compiled from three or
more independent experiments, passed normality tests (KS nor-
mality test and D’Agostino & Pearson omnibus normality test),
and analysed by Student’s t-test or one-way ANOVA as appro-
priate using Graph Pad Prism version 5 (Graph Pad Software, CA,
USA). One-way ANOVA with Bonferroni’s multiple comparison
test was applied to assess the statistical significance of genetic
difference analysis based on NPR3 gene expression, luciferase
activity, cell proliferation, migration, calcium flux and cell con-
traction in response to Ang II. Student’s t-test (two-tailed) was
performed to evaluate the significance of the comparison be-
tween two alleles for AEI, FAIRE, ChIP and the genetic differ-
ences between two genotypes. Differences with P< 0.05 were
considered statistically significant. P< 5 108 was used as a
threshold for genome-wide significance in UKB GWAS.
Supplementary Material
Supplementary Material is available at HMG online.
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